US 11,749,375 B2
Human therapeutic targets and modulators thereof
John Baxter Biggins, Long Beach, NY (US); Brian Roger Bowman, New Rochelle, NY (US); and Gregory L. Verdine, Boston, MA (US)
Assigned to LIFEMINE THERAPEUTICS, INC., Cambridge, MA (US)
Appl. No. 16/646,978
Filed by LIFEMINE THERAPEUTICS, INC., Cambridge, MA (US)
PCT Filed Sep. 14, 2018, PCT No. PCT/US2018/051134
§ 371(c)(1), (2) Date Mar. 12, 2020,
PCT Pub. No. WO2019/055816, PCT Pub. Date Mar. 21, 2019.
Claims priority of provisional application 62/558,744, filed on Sep. 14, 2017.
Prior Publication US 2020/0211673 A1, Jul. 2, 2020
Int. Cl. G16B 20/00 (2019.01); G16B 35/10 (2019.01)
CPC G16B 20/00 (2019.02) [G16B 35/10 (2019.02)] 23 Claims
OG exemplary drawing
 
1. A method comprising steps of:
querying a set of nucleic acid sequences, each of which is found in a fungal strain and comprises a biosynthetic gene cluster; and
identifying within at least one of the fungal nucleic acid sequences an embedded target gene (ETaG) sequence characterized in that it:
is not required for or is not involved in the biosynthesis of the product of the biosynthetic gene cluster;
is within a proximity zone relative to at least one gene in the cluster;
is homologous to a mammalian nucleic acid sequence; and
is optionally co-regulated with at least one biosynthetic gene in the cluster.